Stock Day Media

U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy

October 27, 2020October 27, 2020 Stock Day Media 853 Views BLA, cydy, HIVtherapy, Leronlimab, oneinjection, UK

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

Leronlimab Shows Early, but Promising Clinical Responses in First Two Patients Recovering from Stroke

October 26, 2020October 26, 2020 Stock Day Media 995 Views clinicalresponses, cytodyn, Leronlimab, stroke, twopatients

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines

October 13, 2020October 13, 2020 Stock Day Media 1073 Views chiralpharma, cydy, cytodyn, FDA, Leronlimab, philippines

VANCOUVER, Washington, Oct. 12, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19

August 7, 2020August 7, 2020 Stock Day Media 842 Views covid19, cydy, cytodyn, hiv, Leronlimab

BLA-type submission planned this month in U.K. for HIV combination therapy with 350 mg weekly dose• COVID-19 Phase 2 topline report

BioTech

CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

July 6, 2020July 6, 2020 Stock Day Media 1387 Views covid19, cydy, cytodyn, Leronlimab

This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of

BioTech

CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology

July 2, 2020July 2, 2020 Stock Day Media 1420 Views cydy, Immuno-Oncology, Leronlimab, mechanism

VANCOUVER, Washington, July 02, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company

BioTech

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

May 18, 2020May 18, 2020 Stock Day Media 1153 Views cydy, cytodyn, Leronlimab, phase3trial, remdesivir, threearmcomparitive

VANCOUVER, Washington, May 18, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

Leronlimab

FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 Trial

U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy

Leronlimab Shows Early, but Promising Clinical Responses in First Two Patients Recovering from Stroke

CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial

CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines

CytoDyn’s Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’

After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.’s MHRA Accepts CytoDyn’s Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms

CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19

CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S.

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: